The Times of Israel: Israel expands vaccination campaign to teens aged 16-18
Israel have expanded their COVID-19 vaccination program to include teenagers aged ≥ 16 years, with the first vaccines being given in this age group on January 23.
Initial immunisation in Israel began in December 2020, prioritising health care workers, the elderly and other at-risk groups. To date, 2.5 million people have received a dose of the Pfizer BioNTech COVID-19 vaccine, with 900 thousand of those, also having received their second dose.
要了解更多信息，请点击以下链接：
The Times of Israel: Israel expands vaccination campaign to teens ages 16-18
COVAX announces new agreement, plans for first deliveries
这 COVAX Facility has announced the signing of an advance purchase agreement for up to 40 million doses of the Pfizer/BioNTech COVID-19 vaccine.
COVAX is on track to deliver at least 2 billion doses of COVID-19 vaccines by the end of the 2021, including at least 1.3 billion doses to 92 lower income countries.
For more information please follow the link below:
Gavi: COVAX announces new agreement, plans for first deliveries
ATAGI advice on influenza and COVID-19 vaccines
这 澳大利亚免疫技术咨询小组 (ATAGI) have published advice related to the administration of influenza and COVID-19 vaccines.
Due to a lack of safety and immunogenicity data on the co-administration of these vaccines, it is therefore recommended that influenza and COVID-19 vaccines are not administered on the same day, but with a minimum interval of 14 days. There is no preference regarding the order of vaccine administration, noting that both the Oxford/AstraZeneca and Pfizer/BioNTech COVID-19 vaccines require a 2-dose schedule. If influenza and COVID-19 vaccines are inadvertently administered on the same day or are administered within a shorter timeframe than 14 days, revaccination with either vaccine is not recommended.
To read the advice in full, refer to the link below:
ATAGI advice on influenza and COVID-19 vaccines
Mobilising Australia’s COVID-19 vaccine workforce
The Australian Government have confirmed that COVID-19 vaccine delivery will be carried out by hospitals, general practices, state and commonwealth vaccination clinics, Aboriginal Community Controlled Health Organisations and Pharmacies.
To supplement our already established vaccine workforce, and assist in vaccine delivery to outreach locations, Aspen Medical, Healthcare Australia, International SOS, and Sonic Clinical Services have been contracted to support each jurisdiction in their vaccine program.
To read the announcement in full, follow the below link:
Mobilising Australia’s COVID-19 vaccine workforce
GACVS COVID-19 Vaccine Safety subcommittee meeting to review reports of deaths of very frail elderly individuals vaccinated with Pfizer BioNTech COVID-19 vaccine, BNT162b2
The role of the Global Advisory Committee on Vaccine Safety (GACVS) is to provide independent, expert advice to the World Health Organization on the safety of vaccines.
On January 19 2021 a virtual meeting was held to review all available information on the deaths reported in frail, elderly individuals who had received the Pfizer/BioNTech COVID-19 vaccine. Following this review, it was concluded that vaccination has not contributed to any unexpected or increase in number of fatalities in this patient group. As such, there is no change in recommendations around safety of the Pfizer/BioNTech COVID-19 vaccine.
要了解更多信息，请点击以下链接：
COVID-19 vaccine rollout: Primary care participation in Phase 1b–call for expressions of interest from General Practices
In preparation for the rollout of COVID-19 vaccines in Australia, accredited general practices are invited to express their interest in participating in Phase 1b of the COVID-19 Vaccination Program.
Phase 1b of the COVID-19 Vaccination Program is dedicated to delivering 14.8 million doses of the University of Oxford/AstraZeneca COVID-19 vaccine (dependant on TGA approval).
The Phase 1b priority populations include:
- People aged 70 years and over
- Aboriginal and Torres Strait Islander adults
- Critical and high-risk workers including defence, police, fire, emergency services and meat
processing
- Health care workers other than those prioritised in Phase 1a, including (but not limited to)
hospitals, general practices, pharmacists, allied health, and other healthcare services in the
community
- People at increased risk of severe disease
For further information, including how to register your interest, please follow the link below:
CNN: How some states are administering Covid-19 vaccines at twice the speed of others
Data from the CDC reveals that of the 31 million doses of COVID-19 vaccine that have been distributed to the various jurisdictions in the United States, only 39% (12.2 million doses) have actually been administered. Those states with the highest vaccination rates have suggested that preparation, communication and strategic planning have been vital in vaccine rollout.
要阅读更多信息，请点击以下链接：
CNN: How some states are administering Covid-19 vaccines at twice the speed of others
ABC 电台：尽管有老年人死亡，挪威仍将继续使用辉瑞的新冠疫苗
挪威药品管理局医疗主任 Steinar Madsen 博士接受了 ABC 电台采访，讨论了最近老年人接种辉瑞/BioNTech COVID-19 疫苗后死亡的报道。虽然调查正在进行中，但他强调副作用很少见，挪威将继续使用这种疫苗，作为其 COVID-19 疫苗推广的一部分。
要收听采访，请点击以下链接：
ABC 电台：尽管有老年人死亡，挪威仍将继续使用辉瑞的新冠疫苗
TGA：挪威对老年、非常虚弱患者的 COVID-19 疫苗接种风险进行调查
最近挪威有报道称，接种辉瑞/BioNTech COVID-19 疫苗的 40,000 名老年人中有 30 多人死亡。死亡与接种疫苗后发烧、恶心和腹泻有关。接种疫苗后预计会出现此类不良事件，并且通常是短暂的。记录的死亡病例是非常虚弱的患者，他们的预期寿命只有几周到几个月。
TGA 正在与欧洲监管机构密切合作，进一步调查这些报告，并将确定辉瑞/BioNTech 疫苗的产品信息是否应包含有关体弱、老年人或绝症患者风险的警告。
通过以下链接阅读 TGA 声明的更多内容：
TGA：挪威对老年、非常虚弱患者的 COVID-19 疫苗接种风险进行调查
《华盛顿邮报》：没有冠状病毒的岛国帕劳很快就会为几乎所有人民接种疫苗
人口接近 18,000 人的小岛国帕劳已成功摆脱了 COVID-19 疾病的困扰。作为与美国“自由联合”协议的一部分，帕劳可以获得 Moderna COVID-19 疫苗，并计划到 2021 年 4 月实现几乎所有人口的免疫。
要了解更多信息，请点击以下链接：
《华盛顿邮报》：没有冠状病毒的岛国帕劳很快就会为几乎所有人民接种疫苗